Asarina Pharma AB (publ) (ASAP.ST)
Asarina Pharma AB (publ) operates in the Biotechnology industry of the Healthcare sector, headquartered in Solna, SE. The stock last traded at $0.03, down 31.03% on the session, giving a market capitalisation of $633,959. Its beta of 0.17 implies it has historically moved less than the broad market.
Asarina Pharma AB (publ) is a biotech enterprise, specializing in the research and development of pharmaceutical products. Their key therapeutic agent, Sepranolone, is developed to address menstrual migraine and Tourette syndrome. Founded in 2005, this Solna, Sweden-based company was previously known as Umecrine Mood AB before officially changing its name to Asarina Pharma AB (publ) in 2016.
Asarina Pharma AB (publ) is most often compared with the following Healthcare names: